<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-31054" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Venlafaxine</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Singh</surname>
            <given-names>Dharminder</given-names>
          </name>
          <aff>Kaweah Delta Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Saadabadi</surname>
            <given-names>Abdolreza</given-names>
          </name>
          <aff>Western University/ Kaweah Delta</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Dharminder Singh declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Abdolreza Saadabadi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>26</day>
          <month>2</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-31054.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Venlafaxine is&#x000a0;categorized as a serotonin-norepinephrine reuptake inhibitor (SNRI). It is approved by the US Food and Drug Administration (FDA)&#x000a0;to treat major depressive disorder (unipolar), social anxiety disorder, and panic disorder. In addition,&#x000a0;venlafaxine is commonly used off-label for conditions such as attention-deficit disorder, fibromyalgia, diabetic neuropathy, complex pain syndromes, hot flashes, migraine prevention, posttraumatic stress disorder, obsessive-compulsive disorder, and premenstrual dysphoric disorder. Venlafaxine can be used either as a standalone treatment or as part of a combination therapy regimen with other medications.</p>
        <p>Venlafaxine increases serotonin and norepinephrine levels in the central nervous system by blocking transport proteins and inhibiting their reuptake at the presynaptic terminal. This leads to a greater availability of neurotransmitters at the synapse, ultimately enhancing the activation of postsynaptic receptors.&#x000a0;Antidepressants such as venlafaxine enhance the expression of brain-derived neurotrophic factors and promote neuroplasticity, ultimately decreasing neuroinflammation. This activity focuses on the indications, mechanism of action, administration methods, significant adverse drug reactions, contraindications, and monitoring strategies of venlafaxine in the treatment of psychiatric disorders. This activity underscores how clinicians can direct patient therapy with evidence-based guidelines to achieve optimal treatment outcomes and patient satisfaction within the interprofessional healthcare team.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the appropriate indications for venlafaxine therapy in the management of various psychiatric conditions based on the patient's psychiatric diagnosis and symptomatology.</p></list-item><list-item><p>Screen patients for contraindications to venlafaxine therapy, such as hypersensitivity reactions or concurrent use of monoamine oxidase inhibitors.</p></list-item><list-item><p>Implement appropriate dosing strategies for venlafaxine initiation, titration, and discontinuation based on patient-specific factors and treatment response.</p></list-item><list-item><p>Communicate&#x000a0;with other healthcare providers to coordinate comprehensive care for patients receiving venlafaxine, including monitoring vital signs and laboratory parameters.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=31054&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=31054">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-31054.s2" sec-type="Indications">
        <title>Indications</title>
        <p>The prevalence of mental disorders in the United States is approximately 30%. The global burden of disease statistics shows that&#x000a0;40% of the most important causes of disease worldwide are psychiatric in origin. The pathophysiology behind psychiatric disorders is the imbalance of the complex neurotransmitter system in the brain. The mainstay of management for depression and anxiety&#x000a0;are therapies to modulate these neurotransmitters, including selective serotonin reuptake inhibitors (SSRIs), mixed serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and monoamine oxidase inhibitors (MAOIs). Venlafaxine is&#x000a0;categorized as an SNRI.<xref ref-type="bibr" rid="article-31054.r1">[1]</xref></p>
        <p>
<bold>FDA-Approved Indications</bold>
</p>
        <p>Venlafaxine is approved by the US Food and Drug Administration (FDA)&#x000a0;to treat major depressive disorder (unipolar), social anxiety disorder, and panic disorder.<xref ref-type="bibr" rid="article-31054.r2">[2]</xref><xref ref-type="bibr" rid="article-31054.r3">[3]</xref><xref ref-type="bibr" rid="article-31054.r4">[4]</xref></p>
        <p>
<bold>Off-Label Uses</bold>
</p>
        <p>In addition,&#x000a0;venlafaxine is commonly used off-label for conditions such as attention deficit disorder, fibromyalgia, complex pain syndromes, cataplexy, hot flashes, posttraumatic stress disorder, obsessive-compulsive disorder, premenstrual dysphoric disorder, and migraine prevention.<xref ref-type="bibr" rid="article-31054.r5">[5]</xref> Venlafaxine can be used either as a standalone treatment or as part of a combination therapy regimen with other medications.<xref ref-type="bibr" rid="article-31054.r6">[6]</xref>&#x000a0;The American Academy of Neurology endorses venlafaxine for diabetic neuropathy.<xref ref-type="bibr" rid="article-31054.r7">[7]</xref></p>
      </sec>
      <sec id="article-31054.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Venlafaxine increases serotonin and norepinephrine in the central nervous system by blocking transport proteins and inhibiting their reuptake at the presynaptic terminal. This action leads to increased neurotransmitters available at the synapse and ultimately increases the stimulation of postsynaptic receptors. SNRIs primarily affect serotonergic and noradrenergic neurons, with little or no impact on cholinergic or histaminergic receptors. Venlafaxine is a bicyclic phenylethylamine compound.<xref ref-type="bibr" rid="article-31054.r8">[8]</xref>&#x000a0;Venlafaxine is a more potent serotonin reuptake inhibitor than norepinephrine reuptake. Venlafaxine inhibits serotonin reuptake at lower doses but affects both norepinephrine and serotonin reuptake at higher doses. Antidepressants such as venlafaxine increase brain-derived neurotrophic factor expression and increase neuroplasticity. Venlafaxine is also known to reduce&#x000a0;neuroinflammation.<xref ref-type="bibr" rid="article-31054.r9">[9]</xref><xref ref-type="bibr" rid="article-31054.r10">[10]</xref><xref ref-type="bibr" rid="article-31054.r11">[11]</xref></p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p><bold>Absorption:</bold> Venlafaxine is well absorbed orally (92%) but has a lower bioavailability of 45%. Peak plasma concentrations are typically attained within 2 to 3 hours for immediate-release formulations and 5.5 to 9 hours for extended-release formulations.</p>
        <p><bold>Distribution:</bold>&#x000a0;Venlafaxine's plasma protein binding ranges between 27% and 30%, while its volume of distribution is 7.5 L/kg.</p>
        <p><bold>Metabolism:</bold> Venlafaxine is primarily metabolized by the liver, predominantly through the cytochrome P450 system, particularly the CYP2D6 enzyme.<xref ref-type="bibr" rid="article-31054.r12">[12]</xref></p>
        <p><bold>Elimination:</bold> The elimination half-life of venlafaxine varies depending on the formulation and is approximately 5&#x000b1;2 hours for immediate-release, 6.8&#x000b1;1.6 hours for extended-release besylate, and 10.7&#x000b1;3.2 hours for extended-release hydrochloride. However, this half-life may be prolonged in individuals with renal or hepatic dysfunction. Most venlafaxine is eliminated through urine, with about 87% of the total dose excreted through this pathway. Of this excretion, 5% is an unchanged drug, while 29% is unconjugated <italic toggle="yes">O</italic>-desmethyl venlafaxine and 26% as conjugated&#x000a0;<italic toggle="yes">O</italic>-desmethyl venlafaxine.<xref ref-type="bibr" rid="article-31054.r13">[13]</xref>&#x000a0;Additionally, 27% of the total dose is excreted as minor inactive metabolites.</p>
      </sec>
      <sec id="article-31054.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Available Dosage Forms and Strengths&#x000a0;</bold>
</p>
        <p>Venlafaxine should be taken with food, and patients should avoid combining it with alcohol to prevent increased sedation.&#x000a0;Venlafaxine&#x000a0;is available in both oral tablet and oral capsule forms. The oral tablets come in immediate-release dosage formulations of 25 mg, 37.5 mg, 50 mg, 75 mg, and 100 mg and extended-release dosage formulations of 37.5 mg, 75 mg, 150 mg, and 225 mg. Although the immediate-release tablet can be cut or crushed, the extended-release tablet cannot. Treatment for depression usually begins with immediate-release oral tablets at a total daily dose of 75 mg, divided into 2 or 3 doses.<xref ref-type="bibr" rid="article-31054.r14">[14]</xref></p>
        <p>
<bold>Adult Dosage</bold>
</p>
        <p>Venlafaxine is prescribed only for individuals aged 18 and older and should not be used in children aged 18 or younger. Venlafaxine should be taken with food, and patients should not take it with alcohol, as combining alcohol and venlafaxine can lead to increased sedation. The dosage can increase to 150 mg daily, with a maximum dose of 375 mg daily. The typical starting dose of the extended-release oral tablet is 75 mg daily, taken as a single dose in the morning or evening. The dose of venlafaxine can be increased by 75 mg every&#x000a0;4 days until the maximum dose of 225 mg daily. The FDA-approved dosing of the venlafaxine extended-release (venlafaxine hydrochloride) is given below.</p>
        <list list-type="bullet">
          <list-item>
            <p>Major depressive disorder: The suggested starting dosage of venlafaxine for major depressive disorder is 37.5 to 75 mg/d, with a target dose of 75 mg/d and a maximum dosage of 225 mg/d.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Generalized anxiety disorder: The recommended starting dosage for generalized anxiety disorder is 37.5 to 75 mg/d, with a target dosage of 75 mg/d and a maximum dose of 225 mg/d.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Social anxiety disorder: The recommended starting and target dosage for social anxiety disorder is 75 mg/d.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Panic disorder: The recommended starting dosage for panic disorder is 37.5 mg/d, with a target dosage of 75 mg/d and a maximum dosage of 225 mg/d.</p>
          </list-item>
        </list>
        <p>
<bold>Specific Patient Populations</bold>
</p>
        <p><bold>Hepatic impairment:&#x000a0;</bold>In mild-to-moderate hepatic impairment (Child-Pugh Class A or B), reduce venlafaxine's daily dose by 50%. For severe hepatic impairment (Child-Pugh Class C) or cirrhosis, decrease the total daily dose by 50% or more.</p>
        <p><bold>Renal impairment:</bold>&#x000a0;Adjust the dosage based on creatinine clearance (CrCl). For mild-to-moderate impairment (CrCl 60-89 mL/min or CrCl 30-59 mL/min), reduce the total daily dose by 25% to 50%. For hemodialysis or severe impairment (CrCl &#x0003c;30 mL/min), decrease the daily dose by 50% or more. Due to variability in clearance, individualize dosage as needed.</p>
        <p><bold>Pregnancy considerations:&#x000a0;</bold>In a case-control study involving 30,630 mothers of infants with congenital anomalies and 11,478 control mothers, associations between antidepressants and birth defects were examined.<bold>&#x000a0;</bold>Venlafaxine exhibited associations with birth defects, emphasizing the need for further investigation to confirm these findings. When evaluating the likelihood of birth defects in women who are taking antidepressants, it is important to consider the underlying condition. This highlights the significance of making informed decisions about treatment options by weighing the risks and benefits of intervention against those of untreated depression or anxiety.<xref ref-type="bibr" rid="article-31054.r15">[15]</xref></p>
        <p><bold>Breastfeeding considerations:&#x000a0;</bold>Infants may be exposed to venlafaxine and its active metabolite through breastmilk, with the metabolite detectable in the plasma of most breastfed infants. However, rare reports of concurrent adverse effects might exist. While some experts caution against venlafaxine use during nursing, a safety scoring system suggests it may be possible during breastfeeding. Newborns or preterm infants should be monitored for excessive sedation and adequate weight gain during lactation. Monitoring serum levels of desvenlafaxine may be considered to assess potential toxicity concerns. Bruxism has been reported in&#x000a0;1 infant. Neonatal adaptation syndrome, similar to that observed with other antidepressants such as SSRIs or SNRIs, may occur in newborns of mothers who took venlafaxine during pregnancy.<xref ref-type="bibr" rid="article-31054.r16">[16]</xref></p>
        <p><bold>Pediatric patients:&#x000a0;</bold>Venlafaxine is not FDA-approved for pediatric patients. However, it has been used off-label for cataplexy.<xref ref-type="bibr" rid="article-31054.r17">[17]</xref></p>
        <p><bold>Older patients:&#x000a0;</bold>According to the American Geriatrics Society Beers Criteria (2023), caution&#x000a0;is recommended when using venlafaxine in older adults.<xref ref-type="bibr" rid="article-31054.r18">[18]</xref></p>
      </sec>
      <sec id="article-31054.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Venlafaxine causes a lower frequency of anticholinergic, sedating, and cardiovascular adverse effects but a higher incidence of gastrointestinal complaints, sleep impairment, and sexual dysfunction than TCAs. Additionally, venlafaxine may impair sexual function, resulting in diminished libido, impotence, or difficulty achieving orgasm. Sexual dysfunction frequently results in noncompliance. Sexual dysfunction can sometimes be alleviated by lowering the dose or instituting drug-free weekends and holidays in appropriate patients.</p>
        <p>Venlafaxine is prescribed for the long term, and it carries&#x000a0;severe&#x000a0;risks if not taken as directed or stopped abruptly. Abrupt cessation of venlafaxine can lead to severe adverse effects such as irritability, tiredness, restlessness, anxiety, insomnia, trouble sleeping, nightmares, headache, sweating, dizziness, tingling, or "pins and needles" feeling, shaking, confusion, nausea, vomiting, or diarrhea. Some patients find withdrawal symptoms uncomfortable.<xref ref-type="bibr" rid="article-31054.r19">[19]</xref>&#x000a0; Common adverse effects of venlafaxine include headache, nausea, insomnia, dizziness, somnolence, xerostomia, asthenia, hypertension, impotence, decreased libido, anorgasmia, constipation, weight loss, abnormal dreams, diarrhea, abdominal pain, blurred vision, anxiety, tremor, hypercholesterolemia, and hyponatremia. Severe adverse effects include serotonin syndrome&#x000a0;<xref ref-type="bibr" rid="article-31054.r20">[20]</xref>&#x000a0;and seizures.<xref ref-type="bibr" rid="article-31054.r21">[21]</xref></p>
        <p>Venlafaxine can cause depression exacerbation and hypomania/mania. Venlafaxine can also cause abnormal bleeding, altered platelet function, and anaphylaxis/anaphylactoid reaction. Venlafaxine can cause fatal skin conditions such as Stevens-Johnson syndrome, toxic epidermal necrolysis, and erythema multiforme. Venlafaxine can also cause deterioration of glaucoma angle closure and seizures.<xref ref-type="bibr" rid="article-31054.r22">[22]</xref>&#x000a0;Venlafaxine has implications linking it to the syndrome of inappropriate antidiuretic hormone secretion (SIADH), hypertension, arrhythmia, interstitial lung disease, eosinophilic pneumonia, pancreatitis, and hepatotoxicity.<xref ref-type="bibr" rid="article-31054.r12">[12]</xref></p>
        <p>
<bold>Drug-Drug Interactions</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Venlafaxine can interact with many other medications or herbs.<xref ref-type="bibr" rid="article-31054.r23">[23]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Concomitant administration of desvenlafaxine with other serotonergic drugs should be avoided due to the risk of serotonin syndrome resulting from hyperstimulation of brainstem 5HT-1A receptors. Concurrent use of venlafaxine with SNRIs, SSRIs, triptans, TCAs, opioids, lithium, buspirone, amphetamines, tramadol, tryptophan, and St John's wort is not recommended. Vigilant monitoring for symptoms indicative of serotonin syndrome is imperative when venlafaxine is administered alongside these medications. If serotonin syndrome is suspected, prompt evaluation and consideration for discontinuation of venlafaxine and the other serotonergic agents involved are warranted to mitigate potential adverse effects and ensure patient safety.<xref ref-type="bibr" rid="article-31054.r24">[24]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Venlafaxine should be used cautiously with sedating medications, such as central nervous system depressants and alcohol.&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>The coadministration of venlafaxine with antiplatelet or anticoagulant medications may increase the risk of bleeding. This risk is attributed to venlafaxine's potential impact on serotonin release by platelets. Close monitoring for signs of bleeding is essential when initiating or discontinuing venlafaxine in patients receiving antiplatelet or anticoagulant therapy.&#x000a0;Clinicians should be vigilant for bleeding complications and consider appropriate interventions as necessary.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Patients should not take venlafaxine with MAOIs, linezolid, and methylene blue.&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Venlafaxine should not be&#x000a0;ingested with drugs for weight loss, such as phentermine. Concurrent use of venlafaxine phentermine may cause excessive weight loss, serotonin syndrome, tachycardia, and psychosis.<xref ref-type="bibr" rid="article-31054.r25">[25]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>The risk of bleeding may increase when taking venlafaxine with warfarin and NSAIDs such as aspirin, ibuprofen, and naproxen.&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Clarithromycin, ritonavir, and ketoconazole can inhibit the breakdown of venlafaxine, leading to its accumulation in the body.&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Concurrent use of venlafaxine with lorazepam zolpidem or diphenhydramine can result in increased sedation.&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>The efficacy of metoprolol is reduced when administered with venlafaxine.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>The risk of QT prolongation increases when venlafaxine and haloperidol are administered concurrently.<xref ref-type="bibr" rid="article-31054.r26">[26]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-31054.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Contraindications to venlafaxine include concurrent use of MAOIs. Contraindications for venlafaxine include hypersensitivity to venlafaxine, desvenlafaxine succinate, or excipients. Clinicians should not use venlafaxine if a history of anaphylaxis is evident.&#x000a0;</p>
        <p>
<bold>Box Warning</bold>
</p>
        <p>The FDA has issued a warning regarding antidepressants, including venlafaxine, as they have been associated with an increased risk of suicidal behaviors and thoughts in young patients. Therefore, it is crucial to closely monitor all patients receiving antidepressant treatment for any signs of clinical deterioration or the onset of such thoughts and behaviors.<xref ref-type="bibr" rid="article-31054.r27">[27]</xref>&#x000a0;Furthermore, it is worth noting that venlafaxine is not FDA-approved for pediatric patients.</p>
        <p>
<bold>Warning and Precautions</bold>
</p>
        <p>Caution is necessary when combining venlafaxine with other serotonin modulators. Caution is advisable in heart failure, hyperthyroidism, and those with recent myocardial infarctions, as venlafaxine can raise blood pressure and increase heart rate. Venlafaxine raises the risk of seizures, and prescribers should avoid the drug in patients with a seizure disorder.<xref ref-type="bibr" rid="article-31054.r28">[28]</xref>&#x000a0;Venlafaxine can cause pupillary dilation and block fluid flow in the eye, leading to increased ocular pressure. Patients with glaucoma should have their eye pressures regularly monitored while taking venlafaxine. Venlafaxine should be avoided in patients with uncontrolled angle-closure glaucoma. Venlafaxine is an FDA pregnancy category C drug. Venlafaxine can potentially pass into breast milk and cause adverse effects in breastfed children and should not be used in pregnancy and breastfeeding.</p>
      </sec>
      <sec id="article-31054.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Due to venlafaxine's potential to increase blood pressure and heart rate, monitoring vital signs is imperative. Additionally, monitoring renal and hepatic function is essential to ensure accurate dosing and prevent adverse effects. Furthermore, assessing depression severity using validated tools such as the Montgomery&#x02013;Asberg Depression Rating Scale and PHQ-9 (Patient Health Questionnaire-9) aids in monitoring the effectiveness of treatment and guiding therapeutic decisions.<xref ref-type="bibr" rid="article-31054.r29">[29]</xref><xref ref-type="bibr" rid="article-31054.r30">[30]</xref></p>
      </sec>
      <sec id="article-31054.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>
<bold>Signs and Symptoms of Overdose</bold>
</p>
        <p>Symptoms of an overdose of venlafaxine can include tachycardia, unusual sleepiness, dilated pupils, seizures, vomiting, cardiac arrhythmias, hypotension, muscle aches or pains, or dizziness. Severe toxicity of venlafaxine, especially when combined with other antidepressants such as SSRI, SNRI, or MAOI, can lead to serotonin syndrome. Serotonin syndrome is a possibly life-threatening condition associated with increased serotonergic activity in the central nervous system.</p>
        <p>Serotonin syndrome may present with a spectrum of clinical findings, including autonomic hyperactivity, mental status changes, and neuromuscular abnormalities. Serotonin syndrome characteristically presents with myoclonus, agitation, abdominal cramping, hyperpyrexia, hypertension, and potentially death. No laboratory tests exist to confirm the diagnosis, as serotonin concentrations do not correlate clinically with symptoms. Hunter Toxicity Criteria Decision Rules can be used to form the diagnosis.<xref ref-type="bibr" rid="article-31054.r16">[16]</xref>&#x000a0;</p>
        <p>To meet the criteria, the patient must be taking a serotonergic agent and fulfill&#x000a0;1 of the following conditions:</p>
        <list list-type="bullet">
          <list-item>
            <p>Spontaneous clonus</p>
          </list-item>
          <list-item>
            <p>Inducible clonus with agitation or diaphoresis</p>
          </list-item>
          <list-item>
            <p>The presence of ocular clonus plus agitation or diaphoresis</p>
          </list-item>
          <list-item>
            <p>Tremor with hyperreflexia</p>
          </list-item>
          <list-item>
            <p>Hypertonia with a temperature above 38 &#x000b0;C plus ocular clonus or inducible clonus</p>
          </list-item>
        </list>
        <p>
<bold>Management of Overdose</bold>
</p>
        <p>Management of serotonin syndrome involves promptly discontinuing all serotonergic agents with supportive care to normalize hemodynamics. Patient sedation with benzodiazepines and serotonin antagonists may also be an option.<xref ref-type="bibr" rid="article-31054.r24">[24]</xref>&#x000a0;Cyproheptadine can be an option in the event of a failure with benzodiazepines and supportive care. Cyproheptadine is a histamine-1 receptor antagonist with nonspecific 5-HT1A and 5-HT2A antagonistic properties.<xref ref-type="bibr" rid="article-31054.r31">[31]</xref>&#x000a0;Treatment with propranolol, bromocriptine, or dantrolene is not recommended. Serotonin syndrome symptoms usually resolve within 24 hours of discontinuation of the offending agent.</p>
      </sec>
      <sec id="article-31054.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Interprofessional healthcare team members should monitor vital signs, particularly blood pressure, during venlafaxine therapy. Additionally, venlafaxine patients should undergo regular assessments of renal function and lipid profiles. Close monitoring of psychiatric symptoms, including suicidality, depression, mania, anxiety, or unusual behavior changes, is imperative. Careful attention should be exercised during transitions between venlafaxine and MAOIs, with a recommended 2-week gap before starting venlafaxine after discontinuing an MAOI and a 7-day gap before commencing MAOI therapy after stopping venlafaxine. Collaboration among clinicians and pharmacists is essential to facilitate comprehensive monitoring, ensure patient safety, and optimize therapeutic outcomes. This approach underscores the significance of evidence-based medicine in guiding psychiatric clinical practice while tailoring care to meet individual patient needs.</p>
      </sec>
      <sec id="article-31054.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=31054&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=31054">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/31054/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=31054">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-31054.s11">
        <title>References</title>
        <ref id="article-31054.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Strawn</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Geracioti</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Rajdev</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Clemenza</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Levine</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Pharmacotherapy for generalized anxiety disorder in adult and pediatric patients: an evidence-based treatment review.</article-title>
            <source>Expert Opin Pharmacother</source>
            <year>2018</year>
            <month>Jul</month>
            <volume>19</volume>
            <issue>10</issue>
            <fpage>1057</fpage>
            <page-range>1057-1070</page-range>
            <pub-id pub-id-type="pmid">30056792</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31054.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <collab>Guideline Development Panel for the Treatment of Depressive Disorders</collab>
            <article-title>Summary of the clinical practice guideline for the treatment of depression across three age cohorts.</article-title>
            <source>Am Psychol</source>
            <year>2022</year>
            <month>Sep</month>
            <volume>77</volume>
            <issue>6</issue>
            <fpage>770</fpage>
            <page-range>770-780</page-range>
            <pub-id pub-id-type="pmid">34843274</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31054.r3">
          <label>3</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Dean</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <chapter-title>Venlafaxine Therapy and <italic>CYP2D6</italic> Genotype</chapter-title>
            <person-group person-group-type="editor">
              <name>
                <surname>Pratt</surname>
                <given-names>VM</given-names>
              </name>
              <name>
                <surname>Scott</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Pirmohamed</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Esquivel</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kattman</surname>
                <given-names>BL</given-names>
              </name>
              <name>
                <surname>Malheiro</surname>
                <given-names>AJ</given-names>
              </name>
            </person-group>
            <source>Medical Genetics Summaries [Internet]</source>
            <publisher-name>National Center for Biotechnology Information (US)</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2015</year>
            <month>7</month>
            <day>27</day>
            <pub-id pub-id-type="pmid">28520361</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31054.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alomari</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Bedaiwi</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Ghasib</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Kabbarah</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Alnefaie</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Hariri</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Altammar</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Fadhel</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Altowairqi</surname>
                <given-names>FM</given-names>
              </name>
            </person-group>
            <article-title>Social Anxiety Disorder: Associated Conditions and Therapeutic Approaches.</article-title>
            <source>Cureus</source>
            <year>2022</year>
            <month>Dec</month>
            <volume>14</volume>
            <issue>12</issue>
            <fpage>e32687</fpage>
            <pub-id pub-id-type="pmid">36660516</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31054.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Silberstein</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Holland</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Freitag</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Dodick</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Argoff</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ashman</surname>
                <given-names>E</given-names>
              </name>
              <collab>Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society</collab>
            </person-group>
            <article-title>Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society.</article-title>
            <source>Neurology</source>
            <year>2012</year>
            <month>Apr</month>
            <day>24</day>
            <volume>78</volume>
            <issue>17</issue>
            <fpage>1337</fpage>
            <page-range>1337-45</page-range>
            <pub-id pub-id-type="pmid">22529202</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31054.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Safarova</surname>
                <given-names>TP</given-names>
              </name>
              <name>
                <surname>Yakovleva</surname>
                <given-names>OB</given-names>
              </name>
              <name>
                <surname>Sheshenin</surname>
                <given-names>VS</given-names>
              </name>
              <name>
                <surname>Gavrilova</surname>
                <given-names>SI</given-names>
              </name>
            </person-group>
            <article-title>[Methods of augmentation of antidepressant therapy (on the model of complex therapy with the inclusion of actovegin) in gerontopsychiatric hospital].</article-title>
            <source>Zh Nevrol Psikhiatr Im S S Korsakova</source>
            <year>2018</year>
            <volume>118</volume>
            <issue>6. Vyp. 2</issue>
            <fpage>55</fpage>
            <page-range>55-63</page-range>
            <pub-id pub-id-type="pmid">30346435</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31054.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Price</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Franklin</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Gronseth</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Pignone</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>David</surname>
                <given-names>WS</given-names>
              </name>
              <name>
                <surname>Armon</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Perkins</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Bril</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Rae-Grant</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Halperin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Licking</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>O'Brien</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Wessels</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>MacGregor</surname>
                <given-names>LC</given-names>
              </name>
              <name>
                <surname>Fink</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Harkless</surname>
                <given-names>LB</given-names>
              </name>
              <name>
                <surname>Colbert</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Callaghan</surname>
                <given-names>BC</given-names>
              </name>
            </person-group>
            <article-title>Oral and Topical Treatment of Painful Diabetic Polyneuropathy: Practice Guideline Update Summary: Report of the AAN Guideline Subcommittee.</article-title>
            <source>Neurology</source>
            <year>2022</year>
            <month>Jan</month>
            <day>04</day>
            <volume>98</volume>
            <issue>1</issue>
            <fpage>31</fpage>
            <page-range>31-43</page-range>
            <pub-id pub-id-type="pmid">34965987</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31054.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Saad</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>El-Sahar</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Sayed</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Elbaz</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Helmy</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>Senousy</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Venlafaxine Mitigates Depressive-Like Behavior in Ovariectomized Rats by Activating the EPO/EPOR/JAK2 Signaling Pathway and Increasing the Serum Estradiol Level.</article-title>
            <source>Neurotherapeutics</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>16</volume>
            <issue>2</issue>
            <fpage>404</fpage>
            <page-range>404-415</page-range>
            <pub-id pub-id-type="pmid">30361931</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31054.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zosen</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kondratskaya</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Kaplan-Arabaci</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Haugen</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Paulsen</surname>
                <given-names>RE</given-names>
              </name>
            </person-group>
            <article-title>Antidepressants escitalopram and venlafaxine up-regulate BDNF promoter IV but down-regulate neurite outgrowth in differentiating SH-SY5Y neurons.</article-title>
            <source>Neurochem Int</source>
            <year>2023</year>
            <month>Oct</month>
            <volume>169</volume>
            <fpage>105571</fpage>
            <pub-id pub-id-type="pmid">37451345</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31054.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mansouri</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Naghizadeh</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Ghorbanzadeh</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Alboghobeish</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Amirgholami</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Houshmand</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Cauli</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>Venlafaxine prevents morphine antinociceptive tolerance: The role of neuroinflammation and the l-arginine-nitric oxide pathway.</article-title>
            <source>Exp Neurol</source>
            <year>2018</year>
            <month>May</month>
            <volume>303</volume>
            <fpage>134</fpage>
            <page-range>134-141</page-range>
            <pub-id pub-id-type="pmid">29453978</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31054.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Castr&#x000e9;n</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Monteggia</surname>
                <given-names>LM</given-names>
              </name>
            </person-group>
            <article-title>Brain-Derived Neurotrophic Factor Signaling in Depression and Antidepressant Action.</article-title>
            <source>Biol Psychiatry</source>
            <year>2021</year>
            <month>Jul</month>
            <day>15</day>
            <volume>90</volume>
            <issue>2</issue>
            <fpage>128</fpage>
            <page-range>128-136</page-range>
            <pub-id pub-id-type="pmid">34053675</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31054.r12">
          <label>12</label>
          <element-citation publication-type="book">
            <chapter-title>Venlafaxine, Desvenlafaxine</chapter-title>
            <source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source>
            <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2020</year>
            <month>3</month>
            <day>6</day>
            <pub-id pub-id-type="pmid">31644106</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31054.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sangkuhl</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Stingl</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Turpeinen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Altman</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Klein</surname>
                <given-names>TE</given-names>
              </name>
            </person-group>
            <article-title>PharmGKB summary: venlafaxine pathway.</article-title>
            <source>Pharmacogenet Genomics</source>
            <year>2014</year>
            <month>Jan</month>
            <volume>24</volume>
            <issue>1</issue>
            <fpage>62</fpage>
            <page-range>62-72</page-range>
            <pub-id pub-id-type="pmid">24128936</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31054.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fava</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Benasi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Lucente</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Offidani</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Cosci</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Guidi</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Withdrawal Symptoms after Serotonin-Noradrenaline Reuptake Inhibitor Discontinuation: Systematic Review.</article-title>
            <source>Psychother Psychosom</source>
            <year>2018</year>
            <volume>87</volume>
            <issue>4</issue>
            <fpage>195</fpage>
            <page-range>195-203</page-range>
            <pub-id pub-id-type="pmid">30016772</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31054.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Anderson</surname>
                <given-names>KN</given-names>
              </name>
              <name>
                <surname>Lind</surname>
                <given-names>JN</given-names>
              </name>
              <name>
                <surname>Simeone</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Bobo</surname>
                <given-names>WV</given-names>
              </name>
              <name>
                <surname>Mitchell</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Riehle-Colarusso</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Polen</surname>
                <given-names>KN</given-names>
              </name>
              <name>
                <surname>Reefhuis</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Maternal Use of Specific Antidepressant Medications During Early Pregnancy and the Risk of Selected Birth Defects.</article-title>
            <source>JAMA Psychiatry</source>
            <year>2020</year>
            <month>Dec</month>
            <day>01</day>
            <volume>77</volume>
            <issue>12</issue>
            <fpage>1246</fpage>
            <page-range>1246-1255</page-range>
            <pub-id pub-id-type="pmid">32777011</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31054.r16">
          <label>16</label>
          <element-citation publication-type="book">
            <chapter-title>Venlafaxine</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2024</year>
            <month>1</month>
            <day>15</day>
            <pub-id pub-id-type="pmid">30000251</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31054.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dwyer</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Bloch</surname>
                <given-names>MH</given-names>
              </name>
            </person-group>
            <article-title>Antidepressants for Pediatric Patients.</article-title>
            <source>Curr Psychiatr</source>
            <year>2019</year>
            <month>Sep</month>
            <volume>18</volume>
            <issue>9</issue>
            <fpage>26</fpage>
            <page-range>26-42F</page-range>
            <pub-id pub-id-type="pmid">31511767</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31054.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <collab>By the 2023 American Geriatrics Society Beers Criteria&#x000ae; Update Expert Panel</collab>
            <article-title>American Geriatrics Society 2023 updated AGS Beers Criteria&#x000ae; for potentially inappropriate medication use in older adults.</article-title>
            <source>J Am Geriatr Soc</source>
            <year>2023</year>
            <month>Jul</month>
            <volume>71</volume>
            <issue>7</issue>
            <fpage>2052</fpage>
            <page-range>2052-2081</page-range>
            <pub-id pub-id-type="pmid">37139824</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31054.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ning</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Luo</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Meng</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Luo</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Wan</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lian</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Melgiri</surname>
                <given-names>ND</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>The efficacy and safety of first-line therapies for preventing chronic post-surgical pain: a network meta-analysis.</article-title>
            <source>Oncotarget</source>
            <year>2018</year>
            <month>Aug</month>
            <day>10</day>
            <volume>9</volume>
            <issue>62</issue>
            <fpage>32081</fpage>
            <page-range>32081-32095</page-range>
            <pub-id pub-id-type="pmid">30174798</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31054.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhan</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Cao</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Serotonin Syndrome Induced by a Single Dose of Venlafaxine and Magnesium Valproate.</article-title>
            <source>Psychiatr Danub</source>
            <year>2021</year>
            <season>Summer</season>
            <volume>33</volume>
            <issue>2</issue>
            <fpage>193</fpage>
            <page-range>193-195</page-range>
            <pub-id pub-id-type="pmid">34185746</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31054.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hill</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Coupland</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Morriss</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Arthur</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Moore</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hippisley-Cox</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Antidepressant use and risk of epilepsy and seizures in people aged 20 to 64&#x000a0;years: cohort study using a primary care database.</article-title>
            <source>BMC Psychiatry</source>
            <year>2015</year>
            <month>Dec</month>
            <day>17</day>
            <volume>15</volume>
            <fpage>315</fpage>
            <pub-id pub-id-type="pmid">26678837</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31054.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dubovicky</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Belovicova</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Csatlosova</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Bogi</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Risks of using SSRI / SNRI antidepressants during pregnancy and lactation.</article-title>
            <source>Interdiscip Toxicol</source>
            <year>2017</year>
            <month>Sep</month>
            <volume>10</volume>
            <issue>1</issue>
            <fpage>30</fpage>
            <page-range>30-34</page-range>
            <pub-id pub-id-type="pmid">30123033</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31054.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Woro&#x00144;</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Siwek</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gorostowicz</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Adverse effects of interactions between antidepressants and medications used in treatment of cardiovascular disorders.</article-title>
            <source>Psychiatr Pol</source>
            <year>2019</year>
            <month>Oct</month>
            <day>30</day>
            <volume>53</volume>
            <issue>5</issue>
            <fpage>977</fpage>
            <page-range>977-995</page-range>
            <pub-id pub-id-type="pmid">31955180</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31054.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schoretsanitis</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Augustin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sa&#x000df;mannshausen</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Franz</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gr&#x000fc;nder</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Paulzen</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Antidepressants in breast milk; comparative analysis of excretion ratios.</article-title>
            <source>Arch Womens Ment Health</source>
            <year>2019</year>
            <month>Jun</month>
            <volume>22</volume>
            <issue>3</issue>
            <fpage>383</fpage>
            <page-range>383-390</page-range>
            <pub-id pub-id-type="pmid">30116895</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31054.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Homola</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hieber</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Combination of venlafaxine and phentermine/topiramate induced psychosis: A case report.</article-title>
            <source>Ment Health Clin</source>
            <year>2018</year>
            <month>Mar</month>
            <volume>8</volume>
            <issue>2</issue>
            <fpage>95</fpage>
            <page-range>95-99</page-range>
            <pub-id pub-id-type="pmid">29955552</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31054.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <article-title>Sertraline and venlafaxine: new indication. Prevention of recurrent depression: no advance.</article-title>
            <source>Prescrire Int</source>
            <year>2005</year>
            <month>Feb</month>
            <volume>14</volume>
            <issue>75</issue>
            <fpage>19</fpage>
            <page-range>19-20</page-range>
            <pub-id pub-id-type="pmid">15751171</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31054.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Spielmans</surname>
                <given-names>GI</given-names>
              </name>
              <name>
                <surname>Spence-Sing</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Parry</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Duty to Warn: Antidepressant Black Box Suicidality Warning Is Empirically Justified.</article-title>
            <source>Front Psychiatry</source>
            <year>2020</year>
            <volume>11</volume>
            <fpage>18</fpage>
            <pub-id pub-id-type="pmid">32116839</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31054.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gallagher</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Gallagher</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Butler</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Buggy</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Henman</surname>
                <given-names>MC</given-names>
              </name>
            </person-group>
            <article-title>Venlafaxine for neuropathic pain in adults.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2015</year>
            <month>Aug</month>
            <day>23</day>
            <volume>2015</volume>
            <issue>8</issue>
            <fpage>CD011091</fpage>
            <pub-id pub-id-type="pmid">26298465</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31054.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Levis</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Benedetti</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Thombs</surname>
                <given-names>BD</given-names>
              </name>
              <collab>DEPRESsion Screening Data (DEPRESSD) Collaboration</collab>
            </person-group>
            <article-title>Accuracy of Patient Health Questionnaire-9 (PHQ-9) for screening to detect major depression: individual participant data meta-analysis.</article-title>
            <source>BMJ</source>
            <year>2019</year>
            <month>Apr</month>
            <day>09</day>
            <volume>365</volume>
            <fpage>l1476</fpage>
            <pub-id pub-id-type="pmid">30967483</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31054.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lyndon</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Prieto</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Wajsbrot</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Allgulander</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bandelow</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Efficacy of venlafaxine extended release in major depressive disorder patients: effect of baseline anxiety symptom severity.</article-title>
            <source>Int Clin Psychopharmacol</source>
            <year>2019</year>
            <month>May</month>
            <volume>34</volume>
            <issue>3</issue>
            <fpage>110</fpage>
            <page-range>110-118</page-range>
            <pub-id pub-id-type="pmid">30870236</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31054.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nagy</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Nasir</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Haque</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Judge</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Therapeutic cyproheptadine regimen in serotonin syndrome: Complications after cardiovascular surgery.</article-title>
            <source>Clin Case Rep</source>
            <year>2023</year>
            <month>Jul</month>
            <volume>11</volume>
            <issue>7</issue>
            <fpage>e7720</fpage>
            <pub-id pub-id-type="pmid">37476598</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
